We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+10.76%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$6.85B
AUM Growth
+$678M
Cap. Flow
-$555M
Cap. Flow %
-8.1%
Top 10 Hldgs %
43.77%
Holding
155
New
30
Increased
19
Reduced
23
Closed
29

Top Buys

Rank Stock Value
1
OM icon
Outset Medical
OM
+$156M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$119M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$90.9M
4
RLAY icon
Relay Therapeutics
RLAY
+$88.8M
5
CHRS icon
Coherus Oncology
CHRS
+$57.5M

Top Sells

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$133M
2
KOD icon
Kodiak Sciences
KOD
+$124M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$68.6M
4
VAPO
Vapotherm, Inc. Common Stock
VAPO
+$54.9M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$52.8M

Sector Composition

Rank Sector Weight
1 Healthcare 84.2%
2 Miscellaneous 14.63%
3 Consumer Staples 0.6%
4 Financials 0.25%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
51
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$28.8M 0.42%
329,890
– –
BIIB icon
52
CALL
Biogen
BIIB
$31.9B
$28.4M 0.41%
+100,000
New +$27.9M
MTEM
53
DELISTED
Molecular Templates, Inc.
MTEM
$27M 0.39%
164,942
– –
FUSN
54
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$26.9M 0.39%
2,235,983
– –
IMTX icon
55
Immatics
IMTX
$1.31B
$26.5M 0.39%
+2,500,000
New +$26.3M
VRCA icon
56
Verrica Pharmaceuticals
VRCA
$78.7M
$26.4M 0.39%
341,041
– –
GERN icon
57
Geron
GERN
$842M
$23.4M 0.34%
13,461,538
– –
STOK icon
58
Stoke Therapeutics
STOK
$1.82B
$22.5M 0.33%
671,978
– –
XBI icon
59
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$22.3M 0.33%
+200,000
New +$22.4M
UROV
60
DELISTED
Urovant Sciences Ltd.
UROV
$22.1M 0.32%
2,366,831
– –
PNT
61
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$21.6M 0.31%
+1,500,000
New +$20.5M
PMVP icon
62
PMV Pharmaceuticals
PMVP
$72.7M
$21.5M 0.31%
+605,556
New +$22.3M
WVE icon
63
Wave Life Sciences
WVE
$879M
$21.2M 0.31%
+2,500,000
New +$27.4M
CNCE
64
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$21.1M 0.31%
2,150,641
– –
ISEE
65
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$19.6M 0.29%
3,481,431
– –
COGT icon
66
Cogent Biosciences
COGT
$5.68B
$18.6M 0.27%
+1,988,750
New +$20.7M
VRNA
67
DELISTED
Verona Pharma
VRNA
$18M 0.26%
+2,888,889
New +$20M
CTMX icon
68
CytomX Therapeutics
CTMX
$586M
$17.1M 0.25%
2,577,043
– –
CYPH
69
Cypherpunk Technologies Inc
CYPH
$239M
$16.8M 0.25%
847,650
– –
VTRS icon
70
Viatris
VTRS
$19.1B
$14.9M 0.22%
1,004,419
– –
HRMY icon
71
Harmony Biosciences
HRMY
$2.46B
$14.8M 0.22%
+435,377
New +$15.9M
DRNA
72
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$14.4M 0.21%
800,000
– –
SLDB icon
73
Solid Biosciences
SLDB
$897M
$13.7M 0.2%
449,987
– –
AMWL icon
74
American Well
AMWL
$233M
$13.5M 0.2%
+22,750
New +$12M
MORF
75
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$13.3M 0.19%
487,000
-163,000
-25% -$4.27M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Perceptive Advisors held 155 positions worth $6.85B, up 11% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $555M in Q3 2020, closing 29 positions and reducing 23 holdings. Its most notable exit was Zogenix, Inc., an estimated $133M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Outset Medical worth $142M.

  • Perceptive Advisors's largest Q3 2020 buy was Outset Medical: 189,855 shares worth $142M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2020, an estimated $90.9M increase.
  • Perceptive Advisors's biggest Q3 2020 reduction was Kodiak Sciences, cutting an estimated $124M.
  • Perceptive Advisors fully exited Zogenix, Inc. in Q3 2020, selling an estimated $133M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $6.85B portfolio in Q3 2020.
  • Perceptive Advisors opened 30 new positions and closed 29 in Q3 2020.
  • Perceptive Advisors's portfolio value rose 11% quarter-over-quarter to $6.85B.

Based on Perceptive Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.